HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb

Bioconjugate Chemistry

Volumn 17, Issue 5, 2006, Pages 1109-1115

  Shukla, Rameshwer ^a   Thomas, Thommey P ^a   Peters, Jennifer L ^a   Desai, Ankur M ^a   Kukowska Latallo, Jolanta ^a   Patri, Anil K ^a   Kotlyar, Alina ^a   Baker Jr , James R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRIMERS; TUMORS;

ANTIBODY CONJUGATE; CELL-BE; CELL/B.E; CELL/BE; CELLULAR INTERNALIZATION; DENDRIMER GENERATION; GROWTH FACTOR RECEPTORS; POLYAMIDOAMINE DENDRIMERS; PROPERTY; TUMOR-TARGETING;

MONOCLONAL ANTIBODIES;

DENDRIMER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; POLYAMIDOAMINE;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; INTERNALIZATION; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALIA;

EID: 33749038651     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc050348p     Document Type: Article

References (27)

1. Guillemard, V., and Saragovi, H. U. (2001) Taxane-Antibody Conjugates Afford Potent Cytotoxicity, Enhanced Solubility and Tumor Target Selectivity. Cancer Res. 61, 694-699.
2. Baloglu, E., Miller, M. L., Roller, E. E., Cavanagh, E. E., Leece, B. A., Goldmacher, V. S., and Chari, R. V. J. (2004) Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors. Bioorg. Med. Chem. Lett. 14, 5885-5888.
3. Smallshaw, J. E., Ghetie, V., Rizo, J., Fulmer, J. R., Trahan, L. L., Ghetie, M. A., and Vitetta, E. S. (2003) Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat. Biotechnol. 21, 387-389.
4. Seidl, C., Schrock, H., Seidenschwang, S., Beck, R., Schmid, E., Abend, M., Becker, K. F., Apostolidis, C., Nikula, T., Kremmer, E., Schwaiger, M., and Senekowitsch-Schmidtke, R. (2005) Cell death triggered by alpha-emitting Bi-213-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death. Eur. J. Nucl. Med. Mol. Imaging 32, 274-285.
5. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich. A., and Press, M. F. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712.
6. Olayioye, M. A., Neve, R. M., Lane, H. A., and Hynes, N. E. (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19, 3159-3167.
7. Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W. J., and Leahy, D. J. (2003) Structure of the extracellular region of Her2 alone and in complex with the herceptin Fab. Nature (London) 421, 756-760.
8. Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., and Wood, W. I. (1995) Development of anti-p185her2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 92, 1327-1331.
9. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B. B., Henner, D., Wong, W. L. T., Rowland, A. M., Kotts, C., Carver, M. E., and Shepard, H. M. (1992) Humanization of an anti-p185her2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89, 4285-4289.
10. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., and Norton, L. (1999) Phase II study of weekly intravenous trastuzumab (herceptin) in patients with her2/neu- overexpressing metastatic breast cancer. Semin. Oncol. 26, 78-83.
11. Vogel, C., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., and Stewart, S. J. (2001) First-line, single-agent herceptin (trastuzumab) in metastatic breast cancer: a preliminary report. Eur. J. Cancer 37, 25-29.
12. Patri, A. K., Myc, A., Beals, J., Thomas, T. P., Bander, N. H., and Baker, J. R. (2004) Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjugate Chem. 15, 1174-1181.
13. Thomas, T. P., Patri, A. K., Myc, A., Myaing, M. T., Ye, J. Y., Morris, T. B., and Baker, J. R. (2004) In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules 5, 2269-2274.
14. Wu, G., Barth, R. F., Yang, W. L., Chatterjee, M., Tjarks, W., Ciesielski, M. J., and Fenstermaker, R. A. (2004) Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjugate Chem. 15, 185-194.
15. Kobayashi, H., Reijnders, K., English, S., Yordanov, A. T., Milenic, D. E., Sowers, A. L., Citrin, D., Krishna, M. C., Waldmann, T. A., Mitchell, J. B., and Brechbiel, M. W. (2004) Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin. Cancer Res. 10, 7712-7720.
16. Chiu, S. H., Ueno, N. T., and Lee, R. J. (2004) Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin (R)) conjugated polyethylemmine. J. Controlled Release 97, 357-369.
17. Wartlick, H., Michaelis, K., Balthasar, S., Strebhardt, K., Kreuter, J., and Langer, K. (2004) Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J. Drug Targeting 12, 461-471.
18. Copland, J. A., Eghtedari, M., Popov, V. L., Kotov, N., Mamedova, N., Motamedi, M., and Oraevsky, A. A. (2004) Bioconjugated gold nanoparticles as a molecular based contrast agent: Implications for imaging of deep tumors using optoacoustic tomography. Mol. Imaging Biol. 6, 341-349.
19. Duncan, R., and Izzo, L. (2005) Dendrimer biocompatibility and toxicity. Adv. Drug Delivery Rev. 57, 2215-2237.
20. Roberts, J. C., Bhalgat, M. K., and Zera, R. T. (1996) Preliminary biological evaluation of polyamidoamine (PAMAM) starburst dendrimers. J. Biomed. Mater. Res. 30, 53-65.
21. Patri, A. K., Majoros, I. J., and Baker, J. R. (2002) Dendritic polymer macromolecular carriers for drug delivery. Curr. Opin. Chem. Biol. 6, 466-471.
22. Boas, U., and Heegaard, P. M. H. (2004) Dendrimers in drug research. Chem. Soc. Rev. 33, 43-63.
23. Majoros, I. J., Thomas, T. P., Mehta, C. B., and Baker, J. R. (2005) Poly(amidoamine) dendrimer-based multifunctional engineered nano-device for cancer therapy. J. Med. Chem. 48, 5892-5899.
24. Majoros, I. J., Keszler, B., Woehler, S., Bull, T., and Baker, J. R. (2003) Acetylation of poly(amidoamine) dendrimers. Macromolecules 36, 5526-5529.
25. Thomas, T. P., Myaing, M. T., Ye, J. Y., Candido, K., Kotlyar, A., Beals, J., Cao, P., Keszler, B., Patri, A. K., Norris, T. B., and Baker, J. R. (2004) Biophys. J. 86, 3959-3965.
26. Kukowska-Latallo, J. F., Candido, K. A., Cao, Z. Y., Nigavekar, S. S., Majoros, I. J., Thomas, T. P., Balogh, L. P., Khan, M. K., and Baker, J. R. (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65, 5317-5324.
27. Shukla, R., Thomas, T. P., Peters, J., Kotlyar, A., Myc, A., Baker, J. R. (2005) Tumor angiogenic vasculature targeting with PAMAM dendrimer - RGD conjugates. Chem. Commun. 46, 5739-5741.